John Strickler
Positions:
Associate Professor of Medicine
Medicine, Medical Oncology
School of Medicine
Member of the Duke Cancer Institute
Duke Cancer Institute
School of Medicine
Education:
M.D. 2005
University of Chicago
Residency, Medicine
University of Washington
Fellowship in Hematology-Oncology, Medicine
Duke University School of Medicine
Grants:
Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
Administered By
Medicine, Medical Oncology
Awarded By
National Institutes of Health
Role
Significant Contributor
Start Date
End Date
CGX1321-101
Administered By
Duke Cancer Institute
Awarded By
Curegenix Inc.
Role
Principal Investigator
Start Date
End Date
CO40939
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
Nektar
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
AbbVie M14-064
Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date
Publications:
Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis
Authors
Okeley, NM; Heiser, RA; Zeng, W; Hengel, SM; Wall, J; Haughney, PC; Yap, TA; Robert, F; Sanborn, RE; Burris, H; Chow, LQ; Do, KT; Gutierrez, M; Reckamp, K; Weise, A; Camidge, DR; Strickler, J; Steuer, C; Wang, Z; O'Meara, MM; Alley, SC; Gardai, SJ
MLA Citation
Okeley, Nicole M., et al. “Abstract 5551: SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis.” Clinical Research (Excluding Clinical Trials), American Association for Cancer Research, 2018. Crossref, doi:10.1158/1538-7445.am2018-5551.
URI
https://scholars.duke.edu/individual/pub1393563
Source
crossref
Published In
Clinical Research (Excluding Clinical Trials)
Published Date
DOI
10.1158/1538-7445.am2018-5551
Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).
Authors
Soria, J-C; Strickler, JH; Govindan, R; Chai, S; Chan, N; Quiroga-Garcia, V; Bahleda, R; Hierro, C; Zhong, B; Gonzalez, M; Santiago-Walker, AE; Parekh, TV; Luo, FR; Sullivan-Chang, L; Xie, H; Tabernero, J
MLA Citation
Soria, Jean-Charles, et al. “Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)..” Journal of Clinical Oncology, vol. 35, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2017, pp. 4074–4074. Crossref, doi:10.1200/jco.2017.35.15_suppl.4074.
URI
https://scholars.duke.edu/individual/pub1393709
Source
crossref
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
35
Published Date
Start Page
4074
End Page
4074
DOI
10.1200/jco.2017.35.15_suppl.4074
76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas
Authors
Hurwitz, H; Pitot, H; Strickler, J; Sorensen, JM; Leopold, L; Brill, J; Smith, DC
MLA Citation
Hurwitz, H., et al. “76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas.” European Journal of Cancer, vol. 48, Elsevier BV, 2012, pp. 25–25. Crossref, doi:10.1016/s0959-8049(12)71874-9.
URI
https://scholars.duke.edu/individual/pub929770
Source
crossref
Published In
European Journal of Cancer
Volume
48
Published Date
Start Page
25
End Page
25
DOI
10.1016/s0959-8049(12)71874-9
Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)
Authors
Wainberg, Z; Strickler, J; Gordon, M; Barve, M; Wang, L; Yue, H; Motwani, M; Kasichayanula, S; Naumovski, L; Hamilton, E
MLA Citation
Wainberg, Z., et al. “Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC).” Annals of Oncology, vol. 29, OXFORD UNIV PRESS, 2018, pp. 66–66.
URI
https://scholars.duke.edu/individual/pub1339014
Source
wos
Published In
Annals of Oncology
Volume
29
Published Date
Start Page
66
End Page
66
Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).
Authors
Strickler, JH; Banks, KC; Nagy, RJ; Lanman, RB; Talasaz, A; Corcoran, RB; Kopetz, S
MLA Citation
Strickler, John H., et al. “Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC)..” Journal of Clinical Oncology, vol. 35, no. 4, AMER SOC CLINICAL ONCOLOGY, 2017.
URI
https://scholars.duke.edu/individual/pub1383976
Source
wos
Published In
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Volume
35
Published Date
Associate Professor of Medicine
Contact:
Dept of Medicine, Box 2823, Durham, NC 27710